Mission Pharmacal Header

Mission Pharmacal Header

X

Find Hematology Drugs in Phase III Clinical Development in UNITED KINGDOM

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Shield Therapeutics","sponsor":"Beijing Aosaikang Pharmaceutical","pharmaFlowCategory":"D","amount":"$62.8 million","upfrontCash":"$11.4 million","newsHeadline":"China licence agreement for Feraccru\/Accrufer","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Shield Therapeutics"},{"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics (AKTX) Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria Study","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Akari Therapeutics"},{"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review of Nucala for Patients with Hypereosinophilic Syndrome","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"GSK"},{"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Advances Leadership in Renal Disease with More Than 80 Abstracts at ASN Kidney Week 2020 Reimagined","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AstraZeneca"},{"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s Five Studies of Phase 3 ASCEND Programme of Daprodustat for Patients with Anaemia Due To CKD Meets Primary Endpoints","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"GSK"},{"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Receives CHMP Positive Opinions Recommending Approval of Nucala (mepolizumab) in Three Additional Eosinophil-Driven Diseases","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"GSK"},{"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Food and Drug Administration Accepts New Drug Application for Daprodustat","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"GSK"},{"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Akari Therapeutics"},{"company":"Akari Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$12.7 million","upfrontCash":"Undisclosed","newsHeadline":"Akari Therapeutics Announces $12.75 Million Registered Direct Offering","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Akari Therapeutics"}]

Akari Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Akari Therapeutics Announces $12.75 Million Registered Direct Offering

Details:

Net proceeds from the transaction are expected to support advancement of Akari’s two priority pipeline programs investigating nomacopan (rVA576), a bispecific recombinant inhibitor of complement C5 and leukotriene B4 (LTB4).

Lead Product(s): Nomacopan

Therapeutic Area: Hematology Product Name: rVA576

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Alliance Global Partners

Deal Size: $12.7 million Upfront Cash: Undisclosed

Deal Type: Public Offering September 12, 2022

ASK
US

Upload
your Pipeline Activity

Akari Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic St...

Details:

rVA576 (nomacopan), is a bispecific recombinant inhibitor of C5 complement activation and leukotriene B4 (LTB4) activity in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy .

Lead Product(s): Nomacopan

Therapeutic Area: Hematology Product Name: rVA576

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2022

ASK
US

Upload
your Pipeline Activity

GSK

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

US Food and Drug Administration Accepts New Drug Application for Daprodustat

Details:

Regulatory submission of daprodustat for treatment of anaemia of chronic kidney disease based on ASCEND phase III clinical trial programme, consisting of five trials that all met their primary efficacy and safety endpoints in non-dialysis and dialysis patients.

Lead Product(s): Daprodustat

Therapeutic Area: Hematology Product Name: GSK1278863

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 19, 2022

ASK
US

Upload
your Pipeline Activity

GSK

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

GSK Receives CHMP Positive Opinions Recommending Approval of Nucala (mepolizumab) in Three Additional Eosinophil-Driven Diseases

Details:

Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), for use in three eosinophil-driven diseases; hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA) and chronic rhinosinusitis with nasal polyps (CRSwNP).

Lead Product(s): Mepolizumab

Therapeutic Area: Hematology Product Name: Nucala

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 17, 2021

ASK
US

Upload
your Pipeline Activity

GSK

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

GSK’s Five Studies of Phase 3 ASCEND Programme of Daprodustat for Patients with Anaemia Due To CKD Meets Primary Endpoints

Details:

The most commonly reported adverse events in patients receiving daprodustat across the ASCEND programme included hypertension, diarrhoea, dialysis hypotension, peripheral edema, and urinary tract infection.

Lead Product(s): Daprodustat

Therapeutic Area: Hematology Product Name: GSK1278863

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 16, 2021

ASK
US

Upload
your Pipeline Activity

AstraZeneca

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AstraZeneca Advances Leadership in Renal Disease with More Than 80 Abstracts at ASN Kidney Week 2020 Reimagined

Details:

For roxadustat, more than 40 abstracts present safety and efficacy outcomes in anaemia of chronic kidney disease.

Lead Product(s): Roxadustat

Therapeutic Area: Hematology Product Name: Evrenzo

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: FibroGen

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 20, 2020

ASK
US

Upload
your Pipeline Activity

GSK

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

FDA Grants Priority Review of Nucala for Patients with Hypereosinophilic Syndrome

Details:

If approval is obtained, it would make Nucala the first targeted biologic treatment for patients with this rare and life-threatening disease caused by eosinophilic inflammation.

Lead Product(s): Mepolizumab

Therapeutic Area: Hematology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2020

ASK
US

Upload
your Pipeline Activity

Akari Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Akari Therapeutics (AKTX) Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria Study

Details:

All patients treated with nomacopan achieved the primary endpoint of transfusion independence.

Lead Product(s): Nomacopan

Therapeutic Area: Hematology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

ASK
US

Upload
your Pipeline Activity

Shield Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

China licence agreement for Feraccru/Accrufer

Details:

Shield Therapeutics enters into an exclusive licence agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. .

Lead Product(s): Ferric Maltol

Therapeutic Area: Hematology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Beijing Aosaikang Pharmaceutical

Deal Size: $62.8 million Upfront Cash: $11.4 million

Deal Type: Licensing Agreement January 08, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY